Cerebral arteritis

I9_CEREBRART

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

95

4. Check minimum number of events

None

95

5. Include endpoints

None

95

6. Filter based on genotype QC (FinnGen only)

95

Control definitions (FinnGen only)

Control exclude
I9_CEREBVASC

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 614 387 221
Only index persons 486 311 175
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 53.20 52.39 54.98
Only index persons 49.65 48.58 51.56

-FinnGen-

Key figures

All Female Male
Number of individuals 95 62 33
Unadjusted period prevalence (%) 0.02 0.02 0.01
Median age at first event (years) 48.94 48.69 49.39

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
86
Matched controls
861
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I67.7
ICD-10 Finland
Cerebral arteritis, not elsewhere classified
+∞
81.7
65
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
+∞
34.7
31
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
346.3
26.2
25
*
L04AX01
ATC
azathioprine; systemic
34.5
23.3
30
13
TAB00
NOMESCO Finland
Lumbar puncture
32.1
17.0
22
9
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
15.0
16.9
29
28
XA800
NOMESCO Finland
Neuropsychological investigation
23.6
16.3
23
13
R51.80
ICD-10 Finland
Headache
8.4
14.0
34
62
AA1AD
NOMESCO Finland
CT of head and brain
7.0
13.5
39
91
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
24.8
13.1
18
9
H02AB06
ATC
prednisolone; systemic
5.5
12.2
62
274
R4150
NOMESCO Finland
Neuropsychological rehabilitation
+∞
11.7
11
*
B01AC04
ATC
clopidogrel; oral
7.7
11.0
27
48
I67.6
ICD-10 Finland
Nonpyogenic thrombosis of intracranial venous system
+∞
10.6
10
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
+∞
10.6
10
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
45.7
10.3
12
*
R4120
NOMESCO Finland
Occupational therapy
11.6
9.8
18
19
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
+∞
9.5
9
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
22.9
8.7
12
6
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
99.3
8.6
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
5.0
8.5
30
83
I63.8
ICD-10 Finland
Other cerebral infarction
+∞
8.5
8
*
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
8.5
8
*
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
+∞
8.5
8
*
B01AA03
ATC
warfarin; systemic
5.4
8.4
27
67
H02AB07
ATC
prednisone; oral
5.3
8.0
26
65
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.3
7.9
19
32
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
20.7
7.8
11
6
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.2
7.5
24
59
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
9.3
7.5
15
19
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
+∞
7.4
7
*
I68.2*M32.1
ICD-10 Finland
Cerebral arteritis in systemic lupus erythematosus
+∞
7.4
7
*
L04AA06
ATC
mycophenolic acid; systemic
33.0
7.3
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.6
7.0
41
172
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
29.0
6.3
8
*
R4130
NOMESCO Finland
Speech therapy
29.0
6.3
8
*
XCK00
NOMESCO Finland
Perimetry
7.7
6.3
14
21
PA6AG
NOMESCO Finland
Limited MRI examination of neck vasculature with high intensity magnet
+∞
6.3
6
*
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
+∞
6.3
6
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.5
6.1
22
61
G45.1
ICD-10 Finland
Carotid artery syndrome (hemispheric)
16.5
6.0
9
6

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
6
38.96
15.50
2.3
1.2
—
—
—
0
0
14
14
11.56
12.54
1.4
1.0
19.0
3.8
u/ml
—
5
5
14
7
23.11
10.15
1.9
1.0
—
—
—
0
0
9
0
+∞
9.53
2.0
0.0
10.2
—
mg/g
—
9
0
33
113
3.94
8.62
1.8
1.4
509.1
590.0
titre
0.15
11
28
8
0
+∞
8.45
2.1
0.0
—
—
—
0
0
10
11
10.04
8.23
2.4
1.6
—
—
—
0
0
53
270
3.18
7.15
10.5
9.2
1.2
1.2
inr
0.14
13
90
18
45
4.70
6.99
1.6
2.6
—
—
—
0
0
22
65
4.10
6.92
5.0
6.6
-0.5
2.3
mmol/l
3.95
17
52
37
167
2.99
5.96
3.8
4.2
—
—
—
0
0
12
32
4.15
4.23
3.8
6.3
95.4
93.1
%
0.76
12
32
7
7
10.66
4.08
1.0
1.3
—
—
—
0
0
12
33
4.02
4.07
3.8
5.9
0.6
0.8
%
0.63
12
33
57
372
2.33
3.89
11.7
5.9
0.0
0.0
e9/l
0.09
52
331
57
374
2.31
3.81
11.7
5.8
0.6
0.6
e9/l
0.64
52
330
58
385
2.30
3.75
11.6
5.8
1.9
1.8
e9/l
0.38
53
343
26
124
2.51
3.57
1.4
2.0
—
—
—
0
0
67
480
2.34
3.52
5.7
4.4
85.0
5861.3
e6/l
—
5
10
42
252
2.19
3.39
13.7
5.6
—
—
—
0
0
32
172
2.30
3.36
2.9
1.9
2.6
3.2
mg/l
0.98
27
156
13
45
3.19
3.17
3.7
5.6
—
—
—
0
0
7
12
6.20
3.08
1.0
1.1
—
—
—
0
0
23
112
2.39
2.99
1.3
1.6
—
—
—
0
0
38
230
2.09
2.92
4.5
2.9
24.9
27.4
e6/l
0.07
31
178
38
230
2.09
2.92
3.7
3.4
7.4
7.4
ph
—
7
54
5
6
8.70
2.78
5.4
5.7
12.6
13.8
mg/l
—
5
6
61
447
2.02
2.69
13.9
9.9
4.4
3.8
e9/l
1.65
55
398
12
44
2.98
2.66
5.6
3.9
—
—
—
0
0
10
34
3.17
2.49
4.2
5.0
1.3
1.9
%
—
10
34
18
85
2.38
2.48
1.9
1.5
—
—
—
0
0
10
35
3.08
2.38
3.1
4.2
24.6
24.9
mmol/l
—
10
35
12
47
2.78
2.37
1.1
1.2
246.2
135.2
u/ml
0.33
12
40
30
184
1.92
2.13
8.3
7.1
—
—
—
0
0
12
50
2.60
2.12
1.8
3.6
66.6
73.3
e9/l
—
5
40
40
272
1.81
2.05
6.3
3.3
23.9
68.3
e6/l
0.60
32
198
34
226
1.79
1.85
3.1
3.0
—
—
—
0
0
27
168
1.85
1.81
1.6
1.5
2.4
2.7
g/l
0.24
21
101
11
48
2.46
1.78
1.0
1.7
—
—
—
0
0
46
337
1.71
1.77
3.5
2.5
101.6
100.5
ug/l
0.02
46
307
31
203
1.78
1.76
4.5
2.5
—
—
—
0
0
17
91
2.06
1.74
1.5
1.4
—
—
—
0
0
12
56
2.31
1.69
4.9
3.8
—
—
—
0
0
42
303
1.69
1.69
5.2
3.4
—
—
—
0
0
6
19
3.30
1.69
2.0
1.9
—
—
—
0
0
24
148
1.83
1.65
6.3
3.6
—
—
—
0
0
5
14
3.71
1.63
1.6
1.6
—
—
—
0
0
33
225
1.72
1.62
1.7
1.9
—
—
—
0
0
31
208
1.73
1.61
4.5
2.7
0.1
0.2
e6/l
0.71
25
156
12
58
2.22
1.57
3.2
2.7
3.7
4.0
ug/l
0.08
12
53
18
103
1.92
1.54
1.4
1.2
—
—
—
0
0
12
59
2.18
1.51
1.3
1.8
—
—
—
0
0
21
130
1.79
1.42
4.1
3.0
8.7
38.9
ng/l
1.37
15
90
21
311
0.58
1.35
3.0
3.0
—
—
—
0
0
38
281
1.59
1.33
1.9
1.9
101.9
99.0
pmol/l
0.23
23
132
5
18
2.87
1.30
1.2
1.7
—
—
—
0
0
86
785
2.01
1.23
21.7
12.7
19.7
19.9
mg/l
0.02
78
603
61
511
1.54
1.18
7.7
4.3
—
—
—
0
0
8
41
2.04
1.12
2.9
2.1
71.4
95.9
ng/l
—
8
34
48
391
1.46
1.01
7.2
5.1
0.0
0.0
estimate
—
7
81
15
96
1.67
0.91
1.2
1.3
—
—
—
0
0
17
113
1.61
0.90
1.6
2.8
0.8
0.8
mmol/l
0.72
17
108
47
390
1.41
0.86
5.4
3.7
0.0
0.0
estimate
—
8
81
18
124
1.56
0.83
1.5
1.7
1237.3
1293.6
nmol/l
0.08
13
96
47
393
1.39
0.81
5.7
3.7
0.0
0.0
estimate
—
8
75
0
24
0.00
0.80
0.0
4.5
—
—
—
0
0
13
83
1.66
0.80
1.2
1.8
—
—
—
0
0
5
25
2.05
0.74
1.4
1.5
—
—
—
0
0
72
777
0.70
0.71
5.9
4.2
1.3
1.5
mmol/l
1.83
72
715
7
42
1.72
0.70
1.0
1.2
—
—
—
0
0
5
27
1.90
0.69
4.0
4.8
1.2
1.2
mmol/l
—
5
27
7
44
1.64
0.66
1.0
1.2
—
—
—
0
0
23
177
1.40
0.62
1.2
1.3
0.7
1.1
u/ml
—
7
53
11
72
1.60
0.62
2.0
2.0
—
—
—
0
0
8
54
1.53
0.59
1.1
1.2
—
—
—
0
0
6
36
1.71
0.58
1.0
1.1
—
—
—
0
0
9
61
1.52
0.56
2.6
3.5
—
—
—
0
0
85
806
1.52
0.54
24.1
13.9
139.3
139.7
mmol/l
0.76
85
780
85
807
1.51
0.52
24.4
14.0
4.0
4.0
mmol/l
0.04
85
780
26
212
1.31
0.49
5.8
4.0
0.0
0.0
estimate
—
8
79
41
356
1.27
0.48
16.1
10.2
0.0
0.0
e9/l
0.00
35
291
35
300
1.26
0.45
4.8
3.8
59.2
37.5
ng/l
0.23
27
198
25
205
1.30
0.45
1.2
1.4
—
—
—
0
0
6
91
0.64
0.45
1.2
1.2
—
—
—
0
0
5
31
1.65
0.44
4.6
2.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
20
161
1.31
0.41
1.5
1.2
14.4
38.5
iu/ml
—
5
60
0
16
0.00
0.41
0.0
2.8
—
60.5
—
0
16
0
17
0.00
0.41
0.0
2.4
—
7.4
—
0
17
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
73
687
1.27
0.39
31.3
15.3
330.7
332.3
g/l
0.86
73
681
87
840
1.42
0.31
26.2
14.5
78.2
75.7
umol/l
0.30
87
840
86
833
1.34
0.29
21.3
12.0
—
—
—
0
0
71
743
0.82
0.29
24.9
12.0
38.0
40.4
%
0.94
48
562
8
64
1.27
0.28
1.6
2.5
0.3
0.2
g/l
—
8
59
76
790
0.81
0.28
6.2
4.8
2.4
2.8
mmol/l
4.78
76
724
20
233
0.82
0.28
3.0
3.6
—
—
—
0
0
24
212
1.18
0.22
4.7
2.9
7.7
8.3
mmol/l
0.19
19
183
5
42
1.20
0.22
3.6
3.4
4.1
4.7
pmol/l
—
5
35
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
3.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
4.0
—
0
12
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
105.3
—
0
12
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
58
551
1.14
0.19
4.0
3.6
—
—
—
0
0
7
58
1.22
0.18
6.7
4.3
—
—
—
0
0
87
880
0.87
0.17
34.3
18.6
30.0
30.3
pg
0.83
87
865
87
880
0.87
0.17
34.4
18.6
90.5
91.1
fl
0.71
87
865
17
190
0.87
0.14
4.2
4.5
2.1
1.7
ug/l
0.25
17
173
23
250
0.89
0.13
4.1
3.5
—
—
—
0
0
22
201
1.12
0.13
5.1
3.0
3476.0
370.4
mg/l
0.45
14
135
21
193
1.11
0.11
6.4
5.4
—
—
—
0
0
5
45
1.12
0.10
1.4
2.0
—
—
—
0
0
23
215
1.09
0.08
5.2
3.9
39.9
5.8
mg/mmol
0.78
13
139
5
62
0.80
0.08
1.2
1.4
—
—
—
0
0
6
70
0.85
0.08
3.3
3.5
—
—
—
0
0
8
76
1.06
0.07
1.4
4.0
1.2
1.2
mmol/l
—
8
68
12
109
1.12
0.06
3.3
1.7
—
—
—
0
0
77
782
0.92
0.06
5.7
4.3
4.3
4.7
mmol/l
4.28
77
722
32
311
1.04
0.03
1.7
2.0
—
—
—
0
0
15
152
0.98
0.00
1.3
1.2
1.0
8.0
u/ml
—
6
59
0
5
0.00
0.00
0.0
3.8
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
12.0
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
14.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
10.9
—
0.7
—
0
7
0
8
0.00
0.00
0.0
12.5
—
867.4
—
0
8
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
9
93
0.96
0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
6
62
0.97
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
2074.2
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
17.0
—
1521.5
—
0
8
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint I9_CEREBRART and mortality.

Females

Parameter HR [95% CI] p-value
I9_CEREBRART 2.464 [1.74, 3.48] < 0.001
Birth year 0.994 [0.99, 1.0] 0.153

During the follow-up period (1.1.1998 — 31.12.2019), 75 out of 288 females with I9_CEREBRART died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have I9_CEREBRART.

N-year risk Females Males
1 0.188% No data
5 1.119% No data
10 3.367% No data
15 6.757% No data
20 11.596% No data

Relationships between endpoints

Index endpoint: I9_CEREBRART – Cerebral arteritis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data